Back to Search
Start Over
CD4+ T cells in classical Hodgkin lymphoma express exhaustion associated transcription factors TOX and TOX2: Characterizing CD4+ T cells in Hodgkin lymphoma.
- Source :
-
Oncoimmunology [Oncoimmunology] 2022 Jan 27; Vol. 11 (1), pp. 2033433. Date of Electronic Publication: 2022 Jan 27 (Print Publication: 2022). - Publication Year :
- 2022
-
Abstract
- In classical Hodgkin lymphoma (cHL), the highly abundant CD4+ T cells in the vicinity of tumor cells are considered essential for tumor cell survival, but are ill-defined. Although they are activated, they consistently lack expression of activation marker CD26. In this study, we compared sorted CD4+CD26- and CD4+CD26+ T cells from cHL lymph node cell suspensions by RNA sequencing and T cell receptor variable gene segment usage analysis. This revealed that although CD4+CD26- T cells are antigen experienced, they have not clonally expanded. This may well be explained by the expression of exhaustion associated transcription factors TOX and TOX2 , immune checkpoints PDCD1 and CD200 , and chemokine CXCL13 , which were amongst the 100 significantly enriched genes in comparison with the CD4+CD26+ T cells. Findings were validated in single-cell RNA sequencing data from an independent cohort. Interestingly, immunohistochemistry revealed predominant and high frequency of staining for TOX and TOX2 in the T cells attached to the tumor cells. In conclusion, the dominant CD4+CD26- T cell population in cHL is antigen experienced, polyclonal, and exhausted. This population is likely a main contributor to the very high response rates to immune checkpoint inhibitors in cHL.<br />Competing Interests: A.D. receives research funding from Millenium/Takeda. C.S. is an advisory board member for Curis Inc., AbbVie, Seattle Genetics, and Roche, reports receiving commercial research grants from Bristol-Myers Squibb and Trillium Therapeutics, and remuneration from Bayer and Juno Therapeutics. No potential conflicts of interest were disclosed by the other authors.<br /> (© 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.)
- Subjects :
- Dipeptidyl Peptidase 4 immunology
Humans
Lymph Nodes pathology
Transcription Factors genetics
CD4-Positive T-Lymphocytes
HMGB Proteins biosynthesis
HMGB Proteins immunology
High Mobility Group Proteins biosynthesis
High Mobility Group Proteins immunology
Hodgkin Disease genetics
Hodgkin Disease immunology
Hodgkin Disease metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 2162-402X
- Volume :
- 11
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Oncoimmunology
- Publication Type :
- Academic Journal
- Accession number :
- 35111387
- Full Text :
- https://doi.org/10.1080/2162402X.2022.2033433